The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
Background Concerns exist regarding the pro-oxidant and inflammatory potential of intravenous (IV) iron due to labile plasma iron (LPI) generation. This IRON-CKD trial compared the effects of different IV irons on oxidative stress and inflammation. Methods In this randomized open-label explorative s...
Main Authors: | Xenophon Kassianides, Andrew Gordon, Roger Sturmey, Sunil Bhandari |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2021-03-01
|
Series: | Kidney Research and Clinical Practice |
Subjects: | |
Online Access: | http://www.krcp-ksn.org/upload/pdf/j-krcp-20-120.pdf |
Similar Items
-
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
by: Xenophon Kassianides, et al.
Published: (2021-01-01) -
NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
by: Philip A. Kalra, et al.
Published: (2020-12-01) -
A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
by: S. Bhandari, et al.
Published: (2021-03-01) -
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial
by: Veronika Markova, et al.
Published: (2020-08-01) -
Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
by: I. E. Emrich, et al.
Published: (2020-07-01)